RxDoctor Payments Data

Jaime Gutierrez, MD

Family Medicine · del Rio, TXNPI 1922155506

Payments from drug & device makers

$30,184in general payments, 2019–2025

Across 26 payments — averaging $1160.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$22K
  • Sanofi Pasteur Inc.$8K
  • AbbVie$150
  • Boehringer Ingelheim$124
  • Amgen$73
  • Gilead$60
  • plus $247 from 6 others

What the payments were for

  • Food & beverage$654100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,184 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$66,550
Medicare patients
291
Services billed
687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$104,120
JardianceEmpagliflozin121$74,205
EliquisApixaban183$67,692
XifaxanRifaximin33$65,162
NuplazidPimavanserin Tartrate24$57,704
JanuviaSitagliptin Phosphate89$53,176
MounjaroTirzepatide29$30,468
TradjentaLinagliptin38$29,771
TrulicityDulaglutide22$22,559
FarxigaDapagliflozin Propanediol18$17,206
MyrbetriqMirabegron33$13,331
JanumetSitagliptin Phos/Metformin Hcl13$13,078
EntrestoSacubitril/Valsartan23$11,868
Megestrol Acetate127$11,424
LantusInsulin Glargine,hum.Rec.Anlog106$9,707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$57$104,120107 claims
Boehringer IngelheimJardiance, Tradjenta$124$103,976159 claims
PfizerEliquis$46$67,692183 claims
AbbVieLinzess$150$6,89912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in del Rio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →